Literature DB >> 24770440

Medicare star ratings: stakeholder proceedings on community pharmacy and managed care partnerships in quality.

.   

Abstract

OBJECTIVES: To describe the Medicare star rating system, created by the Centers for Medicare & Medicaid Services (CMS) in 2007; identify quality measures that can potentially be improved through collaboration between health plans and community pharmacy; provide examples of current collaboration between health plans and community pharmacy; and identify collaboration goals, challenges, components, and strategies. DATA SOURCES: National thought leaders at a conference titled CMS Star Ratings: A Stakeholder Discussion, held on March 21, 2013, supplemented with related information from the literature.
SUMMARY: The Medicare star rating system is part of CMS's efforts to define, measure, and reward quality health care. Approximately one-half of the star rating performance measures can be influenced directly by community pharmacists working in conjunction with payers that must meet the quality measures. In 2012, a weighting system for star ratings was implemented. Of 10 triple-weighted ratings, 8 are related directly and indirectly to medication therapy and thus have the potential to be improved by pharmacist intervention. Plan ratings can have a substantial impact on beneficiary enrollment. Since very small improvements in performance measures can translate into large effects on star ratings, concerted efforts to improve pharmacy-related measures could move a plan to a higher star rating; conversely, inattention to areas such as high-risk medications, antidiabetic pharmacotherapy, and medication adherence could lower a plan's star rating. Topics discussed in this article include the Electronic Quality Improvement Platform for Plans and Pharmacies, or EQUIPP, the payer perspective on pharmacies, programs currently under way in community pharmacies, and ways plans and pharmacies can better collaborate with each other.
CONCLUSION: The pharmacist's ability to work directly with patients to improve medication use is a critical factor in improving health plan Medicare star ratings. Health plans and community pharmacies must forge partnerships based on well-defined goals and innovative tactics to ensure care quality consistent with evolving public and private payment models.

Entities:  

Mesh:

Year:  2014        PMID: 24770440     DOI: 10.1331/JAPhA.2014.13180

Source DB:  PubMed          Journal:  J Am Pharm Assoc (2003)        ISSN: 1086-5802


  20 in total

1.  Community pharmacists' and residents' decision making and unmet information needs when completing comprehensive medication reviews.

Authors:  Kacie L McPherson; Omolola A Adeoye-Olatunde; Jayna M Osborne; William R Doucette; Stephanie A Gernant; Heather Jaynes; Shobha Phansalkar; Alissa L Russ-Jara; Margie E Snyder
Journal:  J Am Pharm Assoc (2003)       Date:  2020-01-25

2.  Factors associated with comprehensive medication review completion rates: A national survey of community pharmacists.

Authors:  Margie E Snyder; Heather A Jaynes; Stephanie A Gernant; Wendy M Lantaff; William R Doucette; Karen Suchanek Hudmon; Susan M Perkins
Journal:  Res Social Adm Pharm       Date:  2019-08-02

3.  Deprescribing in Advanced Illness: Aligning Patient, Clinician, and Health Plan Goals.

Authors:  Natasha Parekh; Yael Schenker; Chester B Good; Lynn Neilson; William H Shrank
Journal:  J Gen Intern Med       Date:  2019-02-04       Impact factor: 5.128

Review 4.  New and emerging drugs and targets for type 2 diabetes: reviewing the evidence.

Authors:  Brien Rex Miller; Hanh Nguyen; Charles Jia-Haur Hu; Chihyi Lin; Quang T Nguyen
Journal:  Am Health Drug Benefits       Date:  2014-11

5.  Classifying intervention modifications in the community pharmacy context: A demonstration study.

Authors:  Benjamin S Teeter; Jeremy L Thomas; Geoffrey M Curran; Appathurai Balamurugan
Journal:  J Am Pharm Assoc (2003)       Date:  2020-08-21

6.  Medication Therapy Management Delivery by Community Pharmacists: Insights from a National Sample of Medicare Part D Beneficiaries.

Authors:  Omolola A Adeoye; Joel F Farley; Antoinette B Coe; Deborah L Pestka; Karen B Farris; Alan J Zillich; Margie E Snyder
Journal:  J Am Coll Clin Pharm       Date:  2019-06-29

7.  Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation.

Authors:  Joshua D Brown; Anand R Shewale; Jeffery C Talbert
Journal:  J Manag Care Spec Pharm       Date:  2016-11

8.  Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data.

Authors:  Joshua D Brown; Anand R Shewale; Jeffery C Talbert
Journal:  J Manag Care Spec Pharm       Date:  2017-09

9.  Low-Cost Generic Program Use by Medicare Beneficiaries: Implications for Medication Exposure Misclassification in Administrative Claims Data.

Authors:  Nathan J Pauly; Jeffery C Talbert; Joshua Brown
Journal:  J Manag Care Spec Pharm       Date:  2016-06

10.  Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis.

Authors:  Erin K Buysman; Wing Chow; Henry J Henk; Marcia F T Rupnow
Journal:  BMC Endocr Disord       Date:  2015-11-02       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.